See more : Trevi Therapeutics, Inc. (TRVI) Income Statement Analysis – Financial Results
Complete financial analysis of Mithra Pharmaceuticals SA (MITRA.BR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mithra Pharmaceuticals SA, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Eco (Atlantic) Oil & Gas Ltd. (ECAOF) Income Statement Analysis – Financial Results
- Hersha Hospitality Trust (HT) Income Statement Analysis – Financial Results
- LifeMD, Inc. (LFMD) Income Statement Analysis – Financial Results
- Polygon Real Estate Ltd (POLY.TA) Income Statement Analysis – Financial Results
- RSE Archive, LLC (AHVBS) Income Statement Analysis – Financial Results
Mithra Pharmaceuticals SA (MITRA.BR)
About Mithra Pharmaceuticals SA
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.16M | 67.00M | 22.67M | 9.03M | 96.52M | 57.88M | 32.04M | 22.47M | 20.44M | 19.04M | 17.68M | 14.75M |
| Cost of Revenue | 34.16M | 31.56M | 26.15M | 13.33M | 8.26M | 1.57M | 2.60M | 9.03M | 10.20M | 9.99M | 9.05M | 7.44M |
| Gross Profit | 5.99M | 35.43M | -3.48M | -4.30M | 88.26M | 56.31M | 29.45M | 13.44M | 10.24M | 9.05M | 8.62M | 7.31M |
| Gross Profit Ratio | 14.92% | 52.89% | -15.36% | -47.62% | 91.44% | 97.29% | 91.90% | 59.81% | 50.11% | 47.54% | 48.78% | 49.58% |
| Research & Development | 63.17M | 64.04M | 85.24M | 78.46M | 57.07M | 35.71M | 48.19M | 34.30M | 9.59M | 2.61M | 1.38M | 546.00K |
| General & Administrative | 22.09M | 14.68M | 12.52M | 15.93M | 14.77M | 8.98M | 8.70M | 8.23M | 10.33M | 6.72M | 4.36M | 2.37M |
| Selling & Marketing | 2.27M | 2.10M | 1.87M | 1.43M | 1.54M | 1.98M | 1.73M | 7.57M | 5.01M | 3.03M | 3.53M | 4.22M |
| SG&A | 12.14M | 4.84M | 3.96M | 7.49M | 10.54M | 10.96M | 10.43M | 15.79M | 15.34M | 9.75M | 7.90M | 6.59M |
| Other Expenses | 0.00 | 28.34M | -1.00K | -1.00K | -230.00K | -46.55M | 0.00 | 1.00K | 0.00 | 0.00 | 1.00K | -67.00K |
| Operating Expenses | 75.31M | 68.88M | 89.20M | 85.95M | 67.84M | 90.34M | 79.25M | 54.02M | 24.54M | 12.09M | 9.18M | 7.07M |
| Cost & Expenses | 109.48M | 100.44M | 115.35M | 99.28M | 76.10M | 91.91M | 81.85M | 63.05M | 34.74M | 22.08M | 18.24M | 14.50M |
| Interest Income | 1.75M | 14.03M | 11.77M | 3.50M | 3.32M | 3.46M | 1.70M | 53.00K | 315.00K | 206.00K | 143.00K | 14.00K |
| Interest Expense | 22.90M | 17.03M | 12.12M | 3.56M | 3.37M | 5.37M | 267.00K | 1.26M | 798.00K | 1.20M | 143.00K | 169.00K |
| Depreciation & Amortization | 12.21M | 11.94M | -7.72M | -9.05M | -52.06M | 2.85M | 2.16M | 1.05M | 675.00K | 739.00K | 591.00K | 519.00K |
| EBITDA | -52.77M | -21.50M | -82.26M | -80.38M | 26.19M | -31.18M | -47.64M | -39.41M | -13.59M | -2.19M | -61.00K | 743.00K |
| EBITDA Ratio | -131.42% | -32.09% | -362.89% | -890.14% | 27.14% | 29.19% | -75.28% | -156.08% | -66.52% | -11.50% | -0.20% | 5.04% |
| Operating Income | -69.32M | -33.44M | -92.69M | -90.25M | 20.42M | 14.19M | -26.16M | -35.98M | -14.27M | -2.93M | -557.00K | 248.00K |
| Operating Income Ratio | -172.63% | -49.92% | -408.88% | -999.48% | 21.15% | 24.51% | -81.65% | -160.12% | -69.82% | -15.39% | -3.15% | 1.68% |
| Total Other Income/Expenses | -92.47M | 19.88M | -38.46M | -22.53M | -59.99M | -51.68M | -25.35M | -4.66M | -348.00K | -320.00K | -212.00K | -193.00K |
| Income Before Tax | -161.80M | -13.56M | -126.34M | -112.79M | -33.01M | -37.49M | -51.51M | -40.64M | -14.62M | -3.25M | -769.00K | 55.00K |
| Income Before Tax Ratio | -402.93% | -20.24% | -557.34% | -1,249.01% | -34.20% | -64.78% | -160.75% | -180.86% | -71.52% | -17.06% | -4.35% | 0.37% |
| Income Tax Expense | 11.71M | 46.06M | -9.46M | -20.70M | -6.45M | 9.89M | 13.15M | 5.55M | 4.79M | 293.00K | 759.00K | 682.00K |
| Net Income | -173.50M | -59.62M | -116.88M | -92.09M | -26.56M | -27.61M | -38.36M | -35.09M | -9.82M | -2.96M | -1.53M | -627.00K |
| Net Income Ratio | -432.08% | -88.99% | -515.59% | -1,019.78% | -27.52% | -47.70% | -119.72% | -156.16% | -48.06% | -15.52% | -8.64% | -4.25% |
| EPS | -2.51 | -1.22 | -2.69 | -2.25 | -0.70 | -0.75 | -1.17 | -1.13 | -0.32 | -0.19 | -0.05 | -0.02 |
| EPS Diluted | -2.51 | -1.22 | -2.69 | -2.25 | -0.70 | -0.75 | -1.17 | -1.13 | -0.32 | -0.19 | -0.05 | -0.02 |
| Weighted Avg Shares Out | 69.12M | 49.06M | 43.43M | 40.99M | 37.75M | 36.56M | 32.66M | 31.05M | 30.69M | 15.55M | 30.54M | 30.54M |
| Weighted Avg Shares Out (Dil) | 69.12M | 49.06M | 43.43M | 40.99M | 37.75M | 36.56M | 32.66M | 31.13M | 31.13M | 15.89M | 30.54M | 30.54M |
Source: https://incomestatements.info
Category: Stock Reports